Brandon Capital

MEET US IN STOCKHOLM - Our CEO Professor Darren Kelly Kelly will be in Europe 2-9 November, attending Informa Connect EBD Group #Bioeurope2024.   He is open for meetings with investors, pharma and industry partners to discuss the next stage of our development as we plan for our Phase IIb trials of our novel #GPR68 inhibitor #asengeprast (#FT011).   Asengeprast is a first in class GPR68 proton sensing antagonist (a switch regulating #fibrosis via modulating both anti-fibrotic and anti-inflammatory activity). Certa has successfully completed Phase IIa clinical trial with asengeprast for the treatment of Systemic Sclerosis (#SSc), #scleroderma.   We have a wider pipeline of small molecule candidate drugs that target GPR68, each designed to address different fibrotic indications for example kidney disease (FSGS, DKD, CKD).   Get in touch via the partnering system to meet up or email dkelly@certatherapeutics.com to meet up in Stockholm or London.   #fibrosis #drugdevelopment #clinicaltrial #scleroderma #kidneydisease

🚀Interested in applying for CUREator+ Round Two? Then, join the Brandon BioCatalyst CUREator and ANDHealth teams at an Information Session next week. 📅Monday, 28 October ⏰ 12 pm to 1 pm 📹 Via Zoom Register to secure your spot👇🏽 https://lnkd.in/gZ72n845 Supported by funding from the Medical Research Future Fund (MRFF), CUREator+ offers up to $5 million in non-dilutive funding to support breakthrough biomedtech innovations with clinical and commercial potential. 📝Applications close Wednesday, 4th December, at 12:00 pm (AEDT); further details can be found on our website. https://lnkd.in/g45fjDA7

🚀 Calling on forward-thinking organisations in tech, engineering, manufacturing, healthcare, agtech, biotech, energy, mining…and more! 🚀 Are you ready to drive real change in the diversity of C-suites and boardrooms across Australia’s STEM industries? Join us in shaping the future of leadership by hosting a WILD Board X Observer! WILD Board X is your opportunity to: ✅ Demonstrate genuine commitment to diversity and inclusion. ✅ Access fresh perspectives and insights from exceptional, board-ready female STEM leaders. ✅ Strengthen your succession planning and innovation strategy. By hosting a custom-matched Board X Observer, you'll be part of an immersive 12-month board observership program that empowers talented female leaders while enhancing your board’s strategic edge. Proudly supported by the Department of Industry, Science and Resources, the Board X program is designed to create lasting impact for both observers and participating boards. Join our growing community of Host Boards to create a future of more diverse and innovative STEM leadership for Australia. 🌟 🔗 Interested in joining this movement? Contact anna@wildforstem.com to learn more. Transport Accident Commission (TAC) Murdoch Children's Research Institute (MCRI) Medicines Australia Brandon Capital ANDHealth Australian Academy of Technological Sciences & Engineering National Breast Cancer Foundation (NBCF) Canopus Currus Biologics Pty Ltd Vaxxas Additive Assurance Nourish Ingredients Pollinate Group ElectraLith GlyTherix Ltd MTPConnect #WILDforSTEM #BoardX #DiversityInSTEM #STEMLeadership #Innovation #FutureofSTEM #Inclusion #WomenInLeadership #STEMWomen #BoardLeadership

📢Next week, some of the Brandon Capital team will dive into current and emerging trends alongside local and international biotech leaders at the AusBiotech 2024 Life Sciences Conference. 🎤 Bob Soh - Biotech in 2024: The trends, the opportunities, and what investors are looking for. 🎤 Melissa McBurnie - ESG Reporting: What do investors really want to see and how to get started. 🎤 Michael Bettess - Considerations when investing in early-stage university spin-outs. 📅 Wednesday 30 October to Friday 1 November 📍 Melbourne Convention & Exhibition Centre ☕ From interstate and looking for coffee? Paper Tiger at 10 Queen St is a team favourite and a lovely 20-minute walk across the river from the MECC. The full program is below, and we're looking forward to catching up with you all at the sessions, charging stations, and coffee carts! https://lnkd.in/eP4P3vJA 🌏 #AusBiotech2024 #Biotech #LifeSciences #Innovation #Investment

🌍Congratulations to Brandon Capital portfolio company George Medicines, whose successful Phase III Clinical Trial data has appeared in The Lancet, the Journal of the American Medical Association and the American College of Cardiology over the last few weeks. George Medicines is developing an innovative therapy to address hypertension, one of the world’s most pressing health challenges. 📊 1.2 billion people affected globally ⚠️ Only half receive adequate treatment 💡 There’s a critical need for more effective solutions Abstracts covering results from their Phase III clinical trials from The Lancet, JAMA, Journal of the American Medical Association and the American College of Cardiology 👇🏾 𝗧𝗵𝗲 𝗟𝗮𝗻𝗰𝗲𝘁 Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. https://lnkd.in/ggubSRAG 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗶𝗼𝗻 (𝗝𝗔𝗠𝗔) Is a Low-Dose Triple-Drug Combination Pill Protocol the Answer for Hypertension Control in Sub-Saharan Africa? https://lnkd.in/gB3r47Kn 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗺𝗲𝗿𝗶𝗰𝗮𝗻 𝗖𝗼𝗹𝗹𝗲𝗴𝗲 𝗼𝗳 𝗖𝗮𝗿𝗱𝗶𝗼𝗹𝗼𝗴𝘆 Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension https://lnkd.in/gC55MN4P Based on research developed by Brandon BioCatalyst Member The George Institute for Global Health, we couldn't be more thrilled for the entire George team, including Anthony Rodgers and Mark Mallon, as well as our Brandon Capital Managing Partner Stephen Thompson!

🚀 Did you know the Frontier Health and Medical Research initiative will deliver $700 million to researchers developing new health and medical breakthroughs over the next ten years? 🖥️ The Australian Government Department of Health and Aged Care is hosting a webinar that will cover the initiative's goals, application process, key requirements, and an update on experiences so far. Register 👇🏽

📢 CUREator+ Opens Second Funding Round! 🚀 In partnership with Brandon BioCatalyst and ANDHealth, CUREator+ offers up to $5 million per project in non-dilutive funding for companies pioneering innovative health solutions. Funded by the Australian Federal Government's Medical Research Future Fund (#mrff), this program aims to support the development of: 💡 Therapeutics 🔬 Diagnostics 🦾 Medical and connected devices 📱 Digital health technologies Applications are now open to entrepreneurial researchers, clinical innovators, and founders across Australia. Visit https://lnkd.in/g45fjDA7 to: 📧Schedule time with a CUREator or ANDHealth Analyst 📹Register to attend the webinar  🚀Access the link to submit your Expression of Interest (EOI) EOIs close at 12 pm (AEDT) on December 4, 2024. #Innovation #Healthcare #BrandonCapital #CUREator #MedicalResearch #Biotech #DigitalHealth #Funding #ClinicalResearch

OncroRes is looking for a Senior Firmware Engineer! Incredible opportunity to join a talented team working to improve health outcomes for people diagnosed with breast cancer. The team come from a diverse range of sectors including mining and rail, so we’d encourage you to apply even if you don’t believe you’re a perfect fit.

October is Breast Cancer Awareness Month 🎗💗 Did you know? ▶︎ 20,973 Australians are expected to be diagnosed with breast cancer in 2024.    ▶︎ 1 in 7 Australian women will face a breast cancer diagnosis in their lifetime.  ▶︎ While these statistics are concerning, there is hope - 89 out of every 100 women diagnosed with invasive breast cancer now survive five or more years beyond diagnosis. This October, OncoRes Medical joins the global community in recognising Breast Cancer Awareness Month. We stand in solidarity with all those whose lives have been touched by breast cancer.    We believe in the power of innovation to transform healthcare. That's why we're actively developing technologies with the aim of creating a brighter future for individuals facing breast cancer. #OncoRes #breastcancerresearch #womenshealth #BreastCancerAwarenessMonth  

Registrations are open for the Medicinal Chemistry and Biology Conference, where academia and industry come together to cover: 🔴Methods for hit and target identification 🟢Development of new biologically active entities 🔵Probing complex biology 🟠New approaches to tackling diseases. 📍 Darwin 📅13 to 16 April 2025 👇🏽Explore further and register Brad Sleebs